NXTCNextCure, Inc.

Sign up free
Thesis

Shell of NextCure reborn as Avere via reverse merger; $320M-backed IL-23 asset in psoriasis hinges on Phase 2b efficacy data

Thesis as of Aug 6, 2026

Avere Therapeutics (formerly NextCure) is a clinical-stage biopharmaceutical company developing a targeted therapy for psoriasis that is not yet approved.

NextCure's founding oncology programs, SIM0505 and LNCB74, have been effectively abandoned or transferred, with enrollment halted and LNCB74 transitioned out, as the company was hollowed into a reverse-merger vehicle for Avere Therapeutics and its Hansoh-licensed IL-23 inhibitor AVR-001. The thesis now rests entirely on whether AVR-001 Phase 2b data in psoriasis, expected in H1 2028, demonstrates competitive PASI responses sufficient to support a pivotal program. Phase 1b data showed once-weekly dosing matching a first-generation oral inhibitor at four weeks, but no Phase 2 randomized efficacy exists yet, and pre-merger NextCure holders retain only roughly 1.21% of the combined entity.

Status
Broken

SIM0505 enrollment halted; LNCB74 transferred to LigaChem

Conviction

Current Thesis Drivers

  • AVR-001 Phase 1b: once-weekly matched first-gen oral at 4 weeks
  • Randomized Phase 2b efficacy for AVR-001 unresolved
  • SIM0505 enrollment halted; LNCB74 transferred to LigaChem
  • NextCure holders own ~1.21% of combined Avere entity

What could change the thesis?

  • H1 2028 AVR-001 Phase 2b: competitive PASI response validates; miss ends pivot
  • Merger closing: Avere $320M financing clears, combined entity launches; failure strands programs

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the Thesis, argued

Pipeline

8 programs · 6 catalysts

Quick answers

Is the NextCure (NXTC) investment thesis intact?
No. Readouts currently rates the NextCure Thesis Broken. Shell of NextCure reborn as Avere via reverse merger; $320M-backed IL-23 asset in psoriasis hinges on Phase 2b efficacy data.
What is the next catalyst for NextCure (NXTC)?
The next dated event is Phase 1 results for LNCB74, expected H2 2026, as stated by the company. Also ahead: Phase 2b start for AVR-001, expected early 2027.
How long will NextCure's cash last?
NextCure has said its cash will fund operations into the fourth quarter of 2026 (guidance as of August 6, 2026). It reported $20.1 million in cash as of June 30, 2026.

Other companies we cover in these diseases

Osteogenesis imperfecta
Ultragenyx Pharmaceutical (RARE)

Disease areas: Blood cancers, Breast and gynecologic cancers, Other cancers, Neurology and pain, Skin diseases, Endocrine and bone diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

12 peers tracked

Stress Test